You are here
Case Report: Grade 3 mucositis in a patient under erlotinib treatment and radiotherapy
Presentation by Elika Loir at the TAO Congress on 19/20 November 2015
The patient, a 64-year-old woman who never smoked, is diagnosed with bronchial adenocarcinoma with EGFR mutation (Del19). The examination reveals hypercalcaemia, multiple bone lesions as well as a C3 lesion with recession of the posterior wall and epiduritis. She has a history of Sharp’s syndrome (mixed connective tissue disease) and takes hydroxychloroquine and prednisone.
The first-line treatment for the adenocarcinoma consists of erlotinib and biphosphonates, which the patient tolerates well. In addition, radiotherapy is started on day 30. By day 45, radiotherapy is stopped because the patient has developed grade 2 mucositis. Nevertheless, the mucositis worsens to grade 3 by day 55. After the presentation, the expert panel discusses the development of mucositis under erlotinib treatment and radiotherapy.
This case report is part of the programme “AERIO meets the experts” by the French Association of Residents in Oncology (AERIO) in collaboration with an expert panel (Dr. Mario Dicato, Luxembourg Medical Center, Luxembourg; Dr. Richard Gralla, A. Einstein School of Medicine, New York, USA; Dr. Jeffrey Crawford, Duke Cancer Center, Durham, USA; Dr. Pere Gascon, Hospital Clinic, Barcelona).